NASDAQ: IRD · Life Sciences · 10 alerts · CIK 1228627
Share price
$4.04Close, Nov 16
Market cap
$390M
Shares outstanding
96.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Opus Genetics, Inc. filings on SEC EDGAR ↗
Opus Genetics reported a significant increase in net loss to $120.1 million for the nine months ended September 30, 2026, primarily driven by a $72.8 million fair value change in financial instruments. Despite the loss, the company strengthened its balance sheet through $82.9 million in financing activities, including a note purchase agreement and Series B preferred stock issuance, ending the period with $89.0 million in cash and cash equivalents.
Opus Genetics reported financial results for the third quarter of 2026, highlighting a cash runway extending into 2029. The company achieved several clinical milestones, including full enrollment of its OPGx-LCA5 Phase 3 trial and FDA clearance of the IND for OPGx-RDH12. Additionally, the FDA approval of RYZUMVI for presbyopia triggered a regulatory milestone payment to the company.
Term
Q3 2026
“The last several months have marked a period of tremendous advancement for our leading gene therapy programs. Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.”
George Magrath, M.D., Chief Executive Officer of Opus Genetics
“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams. With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases.”
George Magrath, M.D., Chief Executive Officer of Opus Genetics
Opus Genetics CEO George Magrath Sells $110K of Stock
George Magrath, CEO, sold 28,258 shares of Opus Genetics, Inc. at $3.90 a share, worth $110K in total on Nov 3, 2026. Shares held after the trade: 2,010,636 (-1.4%).
Opus Genetics COO Joseph K. Schachle Sells $17K of Stock
Joseph K. Schachle, COO, sold 4,767 shares of Opus Genetics, Inc. at $3.56 a share, worth $17K in total on Oct 23, 2026. Shares held after the trade: 286,673 (-1.6%).
Opus Genetics President Benjamin R. Yerxa Sells $117K of Stock
Benjamin R. Yerxa, President, sold 33,189 shares of Opus Genetics, Inc. at $3.53 to $3.55 a share (average $3.54) in 2 transactions, worth $117K in total on Oct 23, 2026. Shares held after the trade: 670,917 (-3.7%).
Opus Genetics CFO Robert E. Gagnon Sells $49.6K of Stock
Robert E. Gagnon, CFO, sold 14,000 shares of Opus Genetics, Inc. at $3.55 a share, worth $49.6K in total on Oct 23, 2026. Shares held after the trade: 542,375 (-2.5%).
Opus Genetics CEO George Magrath Sells $34.4K of Stock
George Magrath, CEO, sold 9,591 shares of Opus Genetics, Inc. at $3.58 a share, worth $34.4K in total on Oct 23, 2026. Shares held after the trade: 2,038,894 (-0.5%).
Dr. Ashwath Jayagopal transitioned from his role as Chief Scientific and Development Officer of Opus Genetics, effective October 19, 2026. He has entered into a separation and release agreement that includes a six-month consulting arrangement to provide transition services at a rate of $250 per hour.
Opus Genetics presented positive clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at the Retina in Rio 2026 conference. OPGx-BEST1 showed improved retinal sensitivity in 75% of Cohort 1 participants, while OPGx-LCA5 demonstrated sustained visual improvements through 24 months in adults and 6 months in pediatric patients.
Opus Genetics Insider Foundation Fighting Blindness Retinal Degeneration Fund Sells $2.76M of Stock
Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares of Opus Genetics, Inc. at $4.96 a share, worth $2.76M in total on Sep 30, 2026. Shares held after the trade: 3,236,171 (-14.7%).